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Abstract
Foot-and-mouth disease remains a major plague of livestock and outbreaks are often economically catastrophic. Current
inactivated virus vaccines require expensive high containment facilities for their production and maintenance of a cold-
chain for their activity. We have addressed both of these major drawbacks. Firstly we have developed methods to efficiently
express recombinant empty capsids. Expression constructs aimed at lowering the levels and activity of the viral protease
required for the cleavage of the capsid protein precursor were used; this enabled the synthesis of empty A-serotype capsids
in eukaryotic cells at levels potentially attractive to industry using both vaccinia virus and baculovirus driven expression.
Secondly we have enhanced capsid stability by incorporating a rationally designed mutation, and shown by X-ray
crystallography that stabilised and wild-type empty capsids have essentially the same structure as intact virus. Cattle
vaccinated with recombinant capsids showed sustained virus neutralisation titres and protection from challenge 34 weeks
after immunization. This approach to vaccine antigen production has several potential advantages over current
technologies by reducing production costs, eliminating the risk of infectivity and enhancing the temperature stability of the
product. Similar strategies that will optimize host cell viability during expression of a foreign toxic gene and/or improve
capsid stability could allow the production of safe vaccines for other pathogenic picornaviruses of humans and animals.
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Introduction
Foot-and-mouth disease (FMD) is a highly contagious viral
disease of cloven-hoofed animals including cattle, sheep and pigs.
Infection spreads rapidly through susceptible populations and can
give rise to large scale epidemics, causing debilitation, pain and
loss of productivity. Outbreaks of FMD such as that in the UK in
2001, which resulted in the slaughter of over 6 million animals and
cost in excess of £8 billion, highlight the need for vaccines that
support a ‘vaccinate to live’ policy. Vaccination is currently reliant
on the use of inactivated virus produced in large bioreactors in
high containment facilities. This is unsatisfactory on several
grounds: the set-up and running costs are very high, limiting
global production capacity, storage and supply are constrained by
the poor vaccine stability at ambient temperatures, and it can be
difficult to distinguish vaccinated from infected animals. Thus,
more options for FMD vaccine production are urgently required.
FMDV is a non-enveloped single-stranded RNA virus belong-
ing to the family Picornaviridae. The capsid consists of 60 copies
each of four structural proteins (VP1–VP4). During assembly a
95 kDa polyprotein (P1) is cleaved by the viral 3C protease to yield
VP0 (36 kDa), VP1 (32 kDa) and VP3 (27 kDa) which self-
assemble to form the capsid. Auto-catalytic cleavage of VP0 into
VP2 (28 kDa) and VP4 (8 kDa) occurs during encapsidation of the
viral genome to produce the mature virus [1,2]. During infection
empty particles (hereafter termed natural empty particles) may also
be produced, which resemble the mature virus in structure and
antigenicity, but are inherently less stable [1]. The structural
proteins are arranged in an icosahedral lattice of 12 pentameric
building blocks which are the major structural intermediates for
FMDV assembly and disassembly. The capsids are held together
by electrostatic interactions, hydrogen bonds and weak hydropho-
bic interactions between the inter-pentameric subunits [3,4] and
unlike enterovirus capsids which release RNA by receptor-
mediated uncoating [5,6], FMDV capsids appear to release their
genome by dissociation into pentamers at pH,7.0 and elevated
temperatures. This instability translates into vaccines with limited
shelf-life, necessitating a cold chain in many parts of the world
where they are distributed.
Attempts to produce alternative vaccines have shown that intact
virus particles stimulate the best immune response [7]. Picorna-
virus capsids can be synthesized using recombinant techniques by
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expressing (minimally) the P1 structural protein precursor and the
3C protease that cleaves it, since the capsid proteins spontaneously
assemble to produce empty virus-like-particles(VLPs) [8]. The
inherent problem is balancing the expression of P1 and 3C, the
latter being toxic to cells, especially in the case of FMDV [2,9,10].
We demonstrate here the expression of FMDV VLPs at levels that
are potentially viable commercially. We report the production of
wild-type as well as stabilized VLPs, their characterization by X-
ray crystallography and their ability to induce a sustained
protective immunity in cattle.
Results
Expression strategies for VLPs and assessment of their
stability
Three-dimensional structures for several serotypes of FMDV
[2,3,11,12] reveal the basis for the limited particle stability,
highlighting specific atomic interactions along the interface
between pentameric assemblies [4,13]. This allowed us to pick
histidine 93 of VP2, on the helix adjacent to the icosahedral 2-fold
symmetry axis (Figure 1a) as a target for mutagenesis to a
cysteine (H2093C) in order to form energetically favourable
disulphide bonds across the inter-pentameric interface [14].
Initial production of empty capsids utilised infection of
mammalian cells (RK13) with recombinant vaccinia viruses that
encode a P1–3C expression cassette, where P1 (derived from
FMDV A22) is either wild-type (vA22-wt) or carries the H2093C
mutation in VP2 (vA22-H2093C). This cassette was flanked by 59
and 39 UTRs to permit translation from the FMDV IRES [15]
(Figure S1 in Text S1). Expression of capped transcripts was
driven by a T7 polymerase promoter [14]. Provision of the T7
polymerase by co-infection with vaccinia virus recombinant
vTF7.3, effectively lowers the cytotoxicity due to 3C protease or
its capsid product; use of an inducible promoter regulates the
expression levels of the P1-2A-3C cassette compared to that of a
constitutive promoter [9,16]. Infected cells were pelleted, lysed and
the extracts analysed using 15–45% sucrose gradient sedimenta-
tion. Gradient fractions were collected from the bottom of the
tubes and analysed by western blot using anti-FMDV A22 serum.
FMDV capsid proteins were detected in the bottom half of the
gradients (fractions 4 in Figure 1b top panel), indicative of the
ability of both the wild-type and mutant recombinant capsid
proteins to assemble into empty particles [14].
To investigate the stability of the recombinant particles, aliquots
(from fractions 4 of the wild-type and H2093C gradients shown in
Figure 1b top panel) were subjected to either acidification or
heating to 56uC for 2 h before repeat sedimentation on 15–45%
sucrose gradients, with fractions analysed by western blot. Heat-
treated A22-wt derived proteins remained near the top of the
gradient in fraction 10 (Figure 1b, middle left panel) demon-
strating dissociation. By contrast, proteins derived from heat-
treated A22-H2093C were detected predominantly in fraction 4,
showing that the mutant particles had withstood heating
(Figure 1b, middle right panel). Acidification was to pH 5.2
with sodium acetate buffer. The samples were incubated for
15 min before sucrose gradient sedimentation. Analysis of gradient
fractions by western blot showed that A22-wt capsids dissociated
(Figure 1b, bottom left panel), whereas A22-H2093C capsids
remained intact (Figure 1b, bottom right panel).
To develop a practical method for novel vaccine production we
explored the baculovirus expression system [17]. The same P1-3C
cassettes were inserted into a baculovirus-compatible transfer
vector, pOPINE [18]. In recombinant baculoviruses (bA22-wt and
bA22-H2093C), capsid expression is driven by the baculovirus
promoter p10. Capsid expression was optimised by reducing the
activity and expression of 3C protease and thereby its toxic effects
on the cell: this was achieved by site-directed mutagenesis in the
vicinity of the 3C protease active site to reduce its activity and by
insertion of a frameshift sequence upstream of the 3C gene to
down-regulate its expression [19]. Following infection of suspen-
sion cultures of Sf9 cells [19], capsids were purified by a procedure
similar to that used for mammalian cells. FMDV capsids produced
in insect cells sedimented at the same position on 15–45% sucrose
gradients as those produced using vaccinia virus in mammalian
cells (Figure 2a top panel). A second lower band was observed on
gradients loaded with the extract from insect cells (Figure 2b top
panel). SDS-PAGE confirmed that the upper band harboured
FMDV capsid proteins whilst the lower band contained proteins
from baculovirus nucleocapsids (Figure 2b bottom panel). Yields
ranged from 0.8 mg/ml for A22-H2093C to 1.2 mg/ml for A22-wt.
VP0 was cleaved into VP2 and VP4 to a similar extent in
recombinant A22 wt and H2093C. This type of cleavage had
already been observed with A22 empty particles arising during an
FMDV infection and progressed to completion on short term
storage [2].
Crystallographic analyses of VLPs
In situ room temperature X-ray crystallography [20] was used to
determine the structure of both wild-type and mutant capsids
produced using vaccinia virus at 2.2 A˚ and 2.9 A˚ resolution
respectively. The crystals were essentially isomorphous to those
obtained for both A22 virus and A22 natural empty particles
[2,21], and refinement, using strict 15-fold non-crystallographic
symmetry and real space averaging gave reliable maps and models
for both structures. Diffraction from crystals for baculovirus
expressed particles was indistinguishable, demonstrating that the
particles from both expression systems are iso-structural (data not
shown).
The structures of recombinant A22 empty capsids were very
similar to those previously reported for A22 virus and its natural
empty particles [2,21]. However, one region on the surface of the
particle showed a significant structural difference: residues 171–181
of the VP3 GH loop adopt essentially identical folds in the two
natural particles, whereas in wt and H2093C recombinant particles
their structure is more extended (Figure S2 in Text S1) and
Author Summary
Picornaviruses are small RNA viruses, responsible for
important human and animal diseases for example polio,
some forms of the common cold and foot-and-mouth
disease. Safe and effective picornavirus vaccines could in
principle be produced from recombinant virus-like parti-
cles, which lack the viral genome and so cannot
propagate. However the synthesis of stable forms of such
particles at scale has proved very difficult. Two key
problems have been that a protease required for the
proper processing of the polyprotein precursor is toxic for
host cells and the empty recombinant particles tend to be
physically unstable in comparison to virus particles
containing nucleic acid. This is particularly true in the case
of Foot-and-Mouth Disease Virus (FMDV). Here we report
the production and evaluation of a novel vaccine against
FMDV that addresses both of these shortcomings. Impor-
tantly, the strategies we have devised to produce
improved FMDV vaccines can be directly applied to viruses
pathogenic for humans.
Engineered Picornavirus Vaccine Antigen
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almost identical to that seen in another serotype A virus, A10 [11].
We have previously shown that, for serotype O viruses, the VP3 GH
loop conformation is modulated by changes in the adjacent VP1
GH loop [21], so it is possible that one or more amino acid sequence
changes occurred in the highly variable disordered VP1 GH loop
during native A22 virus replication and account for the repacking of
the VP3 loop (no sequence changes were detected in the ordered
portions of the native A22 virus capsid) [2].
The electron density map for the A22-H2093C mutant particles
showed that the disulphide bond across the 2-fold axis relating two
pentamers was correctly formed whilst A22-wt showed the
expected histidine side-chain density (Figure 3a). A difference
electron density map between the wt and H2093C recombinant
particles (Figure S3 in Text S1) revealed, apart from this
mutated residue, no significant features on the particle surface.
Changes are however apparent on the interior of the particles,
with VP4 being similarly ordered in the recombinant wt particle
and the A22 virus structure [2] whereas only two residues of VP4
were visualized in the electron density map for H2093C
(Figure 3b). It is possible that the greater rigidity of the
H2093C particle inhibits movements required for VP4 to fully
settle into the structure seen in mature virus following cleavage of
VP0. Structural superimposition gives rms deviations in Cas of the
native and mutant recombinant particles of 0.36 A˚ (661 equivalent
residues) and 0.4 A˚ (609 equivalent residues) respectively com-
pared to the A22 virus.
Immunogenicity of VLPs
To characterize the protective immunity induced by recombi-
nant capsids produced with baculovirus, we immunised two
groups of four out-bred cattle each with 12 mg of highly purified
capsids formulated in oil adjuvant. One group received A22-wt
and the other A22-H2093C capsids. All animals were re-
immunised after 3 weeks. There was a rapid induction of
Figure 1. Rational design to produce stable empty capsids of FMDV A22. (a) The crystal structure of FMDV serotype A22 [2] was analysed as
described in Materials and Methods. This led to the prediction and modelling of a potential disulphide bond between pentamers by mutation to
cysteine of VP2 histidine residue 93, located on the a-helix at the two-fold symmetry axis. (b) Western blot analyses of A22-wt and A22-H2093C empty
capsids, expressed from recombinant vaccinia viruses and sedimented through 15–45% sucrose gradients. Each gradient was fractionated from the
bottom. FMDV capsid proteins were detected using an anti-FMDV strain A22 polyclonal antibody raised in guinea pigs. Crude extracts were left
untreated, heated to 56uC for 2 h or acidified to pH 5.2 for 15 min. Following both heat and acid treatments A22-H2093C capsids remained intact
and migrated to fraction 4, as before treatment, whereas A22-wt capsids fractured, remaining near the top of the gradient in fraction 10.
doi:10.1371/journal.ppat.1003255.g001
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neutralising antibodies after primary immunisation. The mean
antibody titre of both groups was greater than 5.5 (Log2) which is
considered protective [22]. There was a significant increase in
virus neutralising antibody titres (VNT) post-boost and antibodies
were maintained at high titres, greater than 6 (Log2), up to 22
weeks post-immunisation, but had reduced to pre-boost levels after
34 weeks in both groups of animals (Figure 4). Throughout the
experiment there were no significant (P.0.05) differences in titres
between animals vaccinated with wild-type empty capsids and
those vaccinated with mutated empty capsids.
At 34 weeks post immunisation the animals, plus two non-
vaccinated control animals, were challenged by direct inoculation
into the tongue with live A22 virus. Two of the four animals
immunised with wild-type capsids and three of the four immunised
with mutated capsids were fully protected using the criteria
described in the European pharmacopeia [22]. The two control
animals succumbed to full clinical signs (e.g. vesicular lesion of all
four feet). Large quantities of viral genome were detected in their
sera (greater than 6.5 log10 genomes/ml) for three or four days
(Figure 5c). In contrast, lower quantities of viral genome were
detected in the vaccinated animals (Figure 5a and 5b). The total
amount of virus produced, estimated by computing the area under
the curve (AUC) for copy number versus time, showed that there
were no significant differences in AUC between animals vacci-
nated with A22-wt empty capsids and those vaccinated with A22-
H2093C empty capsids (P = 0.23), whilst the AUC was signifi-
cantly higher for non-vaccinated compared with vaccinated
animals (P = 0.04).
Discussion
Here we have demonstrated the production of safe, effective
FMDV empty capsids that do not require bio-containment during
manufacture. Furthermore, enhanced stability of the empty
capsids will reduce losses during production, storage and transport
whilst maintaining antigenic structure and immunogenicity. In
addition the complete absence of FMDV non-structural proteins
from the vaccine formulation will allow the development of
diagnostic tests to discriminate between infected and vaccinated
animals (DIVA).
Disulphide bonds are used to stabilise many extracellular
proteins and also certain virus capsids [23]. Such covalent cross-
links are more robust than the non-covalent interactions that
generally hold protein assemblies together. Here we have
rationally engineered a disulfide bond by mutating a single
histidine residue at position 93 of VP2 located at the icosahedral 2-
fold axis between adjacent pentamers [4]. Baculovirus expressed
wild-type and stabilised capsids produced equivalent titres of
neutralising antibodies, following a standard immunisation regi-
men, over a 34 week period post immunisation. These results
inform the debate on the effect of increased antigen stability on
immunogenicity. Delamarre et al [24] showed that for two
Figure 2. Sucrose gradient purification and SDS PAGE analysis of A22-wt and A22-H2093C recombinant capsids. The extracts from
either 262125 cm2 roller flasks of HEK293T cells co-infected with recombinant vaccinia viruses, vA22-wt+vTF7-3 or vA22-H2093C+vTF7-3 (a) or from
300 ml culture of Sf9 cells infected with recombinant baculovirus virus, bA22-wt or bA22-H2093C (b) were each loaded onto a 36 ml 15–45% sucrose
gradient and centrifuged at 21,000 rpm for 22 h at 12uC (SW32 rotor, Beckman). Bands were visualised by illumination of the gradients from the top
with a halogen fibre optic light source (Schott). Fractionation of the lower halves of the gradients was in 13 aliquots of 1 ml (fractions 1–13) and 3
aliquots of 2 ml (fractions 14–16) collected from the bottom: 10 ml each from fractions 2 to 15 were analysed on 4–12% acrylamide Novex NuPAGE
gels (Invitrogen).
doi:10.1371/journal.ppat.1003255.g002
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proteins with the same T cell and B cell epitopes but with different
susceptibilities to lysosomal proteolysis, mediated by single point
mutations, less digestible forms induced more efficient T cell
priming and antibody responses. In contrast, recent studies with a
model antigen in mice suggested that enhanced conformational
stability resulted in reduced antigenicity [25]. Although as yet we
do not know if forming a disulphide bridge will be possible for all
serotypes, especially in the baculovirus expression system, our
results demonstrate that capsid stability can be augmented without
compromising immunogenicity and this might be a general tactic
for improving vaccine efficacy. The rational structure-based
approach initiated here should in principle allow the tuning of
these parameters to match the particular circumstances of different
viruses. For instance, enhancing the stability of capsids for highly
prevalent FMDV serotype O, which are more labile than those of
A22 [26]. Recent work on EV71 has demonstrated that
maintaining the proper positions of the 2-fold helices (which
harbour the H2093C mutation in FMDV) is essential for
maintaining native antigenicity [6], suggesting that the approach
we have demonstrated here may be applicable across a wide range
of human and animal picornaviruses, including polioviruses and
coxsackieviruses.
Figure 3. Structure analysis of A22-wt and A22-H2093C empty capsids. (a) The electron density map for A22-wt (left panel) presents the
expected histidine side chains for VP2 residue 93 whereas the map for A22-H2093C (right panel) shows the disulphide density at the two-fold axis
between pentamers. (b) Side by side ribbon drawings of the recombinant empty capsid protomers and beneath the individual VP1, 2 and 4 proteins.
There was no difference between the A22-wt and A22-H2093C capsids on the exterior surface; significant disorder observed on the interior of the
A22-H2093C capsids is shown as thickened lines and corresponds to the N terminus of VP1 (residues 1 to 12) and VP4 (residues 15 to 38 and 65 to 80)
located near the 3-fold axes. To a lesser extent residues 38–41 in VP2 were also disordered.
doi:10.1371/journal.ppat.1003255.g003
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Materials and Methods
Vaccinia virus transfer vectors
An expression cassette based on the sequence of FMDV A22 Iraq
was designed (Figure S1 in Text S1), synthesized de novo
(Geneart) and cloned into the vaccinia virus transfer vector pBG200
[9] downstream of the T7 promoter. Substitution of a BstEII-SpeI
fragment with a sequence encoding the H2093C mutation
converted the pBG200-A22-wt plasmid to pBG200-A22-H2093C.
Generation and selection of vaccinia virus recombinants
The recombinant viruses were made by transfecting pBG200-
A22-wt and pBG200-A22–H2093C into CV-1 cells infected with
vaccinia virus (VV) strain WR. Recombinant VVs (with an
interrupted thymidine kinase gene) were selected in HuTK-143
cells using 5-bromo-2-deoxyuridine. Three rounds of plaque
purification in conjunction with screening by PCR using
FMDV-specific primers were carried out to get stable recombinant
VVs. These were amplified in RK13 cells and virus stocks titrated
by plaque assay on BS-C-1 cells.
All mammalian cells were grown in DMEM supplemented with
10% FCS and appropriate antibiotics at 37uC.
Initial sedimentation of empty capsids produced via
vaccinia virus
A single 175 cm2 flask of RK13 cells was dually infected with
either vA22-wt or vA22-H2093C at an MOI 10 and vTF7.3 at an
MOI 5. After 24 h cells were harvested by centrifugation at
2,000 g for 5 min at 4uC and the pellet resuspended in 1 ml 0.5%
Ipegal (Sigma) in 40 mM sodium phosphate, 100 mM NaCl
pH 7.6. The sample was incubated on ice for 20 min, clarified,
loaded onto a 15–45% sucrose gradient and spun for 20 h at
22,000 rpm (SW41 rotor, Beckman) at 12uC. Each gradient was
fractionated into 12 fractions of 1 ml and aliquots were analysed
by western blotting.
Thermo-stability/pH stability assay
A 200 ml aliquot of the empty capsid-containing fraction
identified during the initial sedimentation experiment (see above),
was diluted 1/3 either (i) with phosphate buffer pH 7.6 and
incubated in a water bath at 56uC for 2 h or (ii) with 50 mM sodium
acetate buffer pH 4.6, to give a final pH of 5.2 and incubated at
room temperature for 15 min before neutralisation with NaOH.
Treated samples were loaded onto 15–45% sucrose gradients,
centrifuged and fractionated as above. Each fraction was precip-
itated with an equal volume of saturated ammonium sulphate
overnight at 4uC. Precipitates were collected by centrifugation at
16,000 g for 15 min at 4uC and analysed by western blot.
Expression and purification of empty capsids from
mammalian cells
HEK293 cells grown in 262125 cm2 roller flasks were dually
infected as described above. After 20 h, cells were pelleted at
Figure 4. Virus neutralising antibody titres pre-challenge. The
group mean virus neutralising antibody titres (Log2) for animals
inoculated with A22-wt (black line) or A22-H2093C (grey line) are
shown from week 0 to week 34. All animals were vaccinated on week 0
and week 3. Blood samples were taken at weekly intervals until week 6
and then on week 22 and finally on week 34 when challenge with live
virus was carried out. Error bars represent the standard error of the
mean.
doi:10.1371/journal.ppat.1003255.g004
Figure 5. Virus genome detection. The quantity of viral genome
(Log10/ml) was determined by quantitative real-time PCR in serum
samples from each animal on days 0–7 and 9 post-challenge. Individual
data for animals vaccinated with (a) A22-wt, (b) A22-H2093C and for
non-vaccinated control animals (c). Clinical signs were detected in two
of the four animals that had received wild-type empty capsid (FMD140
and FMD143) and in one of the four animals immunised with mutated
capsids (FMD144). Both non-vaccinated control animals showed overt
clinical signs.
doi:10.1371/journal.ppat.1003255.g005
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3,500 g for 30 min at 4uC. Pellets were resuspended in phosphate
buffer and lysed with 0.5% Igepal on ice for 20 min. Lysates were
clarified at 10,000 g for 20 min at 4uC and the resulting pellets
resuspended in a small volume of buffer for re-extraction with 1
volume of chloroform. The aqueous phases were pooled with the
clarified extracts and pelleted over 30% sucrose cushions at
105,000 g for 5 h at 12uC. Pellets were resuspended in a small
volume of buffer, treated with 200 mg/ml RNAse A in the
presence of 0.1% Igepal for 30 min on ice, clarified and loaded
onto a 15–45% sucrose gradient. Following centrifugation at
54,000 g for 22 h at 12uC, the gradient was fractionated and
fractions analysed by SDS-PAGE. Sucrose was removed by
desalting with a spin column (Zeba, Pierce) and samples
concentrated by ultrafiltration (Amicon).
Baculovirus transfer vector
pTri-EX-derived plasmid pOPINE was used for In-Fusion
cloning [18] of the FMDV coding sequence from pBG200-A22-wt
resulting in pOPINE-A22-wt [19]. An overlapping PCR proce-
dure which exchanged a P1 region for a fragment bearing the
H2093C mutation resulted in plasmid pOPINE-A22-H2093C.
Subsequent alterations within the P1-2A-3C expression cassette in
order to down-regulate the 3C protease were as described [19].
Generation of baculovirus recombinants and insect cell
expression
Sf9 cells were grown in Insect-XPRESS (Lonza) supplemented
with 2% FCS and antibiotics at 27.5uC. Transfer vector and
AcMNPV bacmid KO1629 (0.5 mg of each) were mixed in the
presence of 3 ml Fugene (Roche) for 20 min at room temperature
and used to transfect Sf9 cells at a density of 1.26106/well in a 6-
well plate. Since baculovirus DNA with gene knockout 1629 will
not initiate an infection unless rescued by recombination with a
baculovirus transfer vector, the AcMNPV harvested in the culture
supernatant after 5 days was 100% recombinant virus [19]. Virus
stocks were produced by infecting Sf9 cells at a confluence of 70%
with 200 ml recombinant per 175 cm2 flask and harvested from
culture supernatants after 5 days. For the expression of empty
capsids, Sf9 cells at a density of 1–2 106/ml were infected with 1/
10 volume of baculovirus stock. After 3 days virus extraction was
as described for mammalian cells except that lysis was with 1%
Triton X-100 in the presence of 5 ml/ml protease inhibitor
cocktail (Sigma).
Molecular modelling and disulphide design
The crystal structures of FMDV serotypes A10 [11], A22 [2]
and O1bfs [3] were inspected and amino acid residues involved in
inter-pentameric interactions were identified. An energetically
favourable disulphide bond was predicted by manually measuring
the pair-wise Cai-Caj and corresponding Cbi-Cbj distances using
COOT [27].
Crystallisation and data collection
Crystals were grown by the sitting-drop vapour diffusion
method in Crystalquick X plates (Greiner Bio-One) using 100 nl
virus plus 100 nl precipitant dispensed with a Cartesian liquid
dispensing robot as described previously [28]. Micro-crystals of
A22-wt empty capsids (3 mg/ml) with average dimensions of
5065065 mm3 and A22-H2093C (2.3 mg/ml) with average
dimensions of 3063065 mm3 grew within 1 week at 294K with
4 M ammonium acetate, 100 mM bis-Tris Propane, pH 7.0.
Optimisation by varying the concentration of precipitant and pH
around the initial condition produced sufficient crystals for
structural solution. A 20620 mm2 beam (l= 0.9778 A˚; I24
micro-focus beamline, Diamond), was used for in situ diffraction
image collection [20] at 294 K on a Pilatus 6 M detector.
Structure determination, refinement and phasing
The structures of A22-wt and A22-H2093C were solved by
molecular replacement. The orientation of the particles (obtained
from a self-rotation function) was found to be the same as for the
native A22 virus structure (PDB id: 4GH4). Hence the coordinates
and non-crystallographic symmetry (NCS) operators from native
virus were used for the refinement. Initial estimates of phases were
obtained by rigid body refinement with CNS [29]. Iterative
positional and B-factor refinement (via CNS) used strict NCS
constraints (Table S1 in Text S1). Phases were further improved
by 15-fold cyclic NCS averaging using the General Averaging
Program (GAP, D Stuart and J. Grimes, unpublished). There was
good agreement between the observed data and those calculated
from the averaged electron density map of R = 10.4% and
CC = 97% for the wild-type and R = 12.3% and CC = 95% for
the mutant. Model building used COOT [27].
Cattle vaccination, challenge and clinical assessment
Two groups of four 100 to 150 kg Holstein Friesian calves were
vaccinated with either A22-wt or A22-H2093C capsids. Each
animal received 12 mg of purified capsid formulated in oil adjuvant
(Seppic 206B) as an intramuscular injection on week 0 and week 3
of the study. All eight animals plus two non-vaccinated control
animals were needle challenged intradermolingually with 16105
TCID50 of cattle adapted FMDV A22 on week 34. Animals were
examined clinically and blood sampled from the day of challenge
until day 9. Cattle were considered protected if lesions could not
be detected at sites distal from the inoculation point. Animal
experimentation was approved by the Pirbright Institute (PI)
ethical review board under the authority of a Home Office project
licence in accordance to the Home Office Guidance on the
Operation of the Animals (Scientific Procedures) Act 1986 and
associated guidelines.
Titration of neutralising antibodies
Sera from the 8 immunised cattle and control sera from 2 non-
vaccinated animals were prepared from blood samples. Their
neutralising activities were determined as reported previously;
testing was in duplicate, in serial 2-fold dilutions and endpoints
calculation was made as described [22]. Titres of FMDV-specific
antibodies are expressed as the reciprocal value of the highest
dilution giving $50% neutralisation of homologous virus growth.
qRT-PCR analysis of viral load in sera
Total nucleic acid was extracted from 200 ml of serum and
automated reverse transcription procedures were performed
incorporating homologous FMDV RNA standards. Real-time
PCR amplification was performed using A22 specific primers and
standard curves constructed to provide a measure of the number
of FMDV genome copies [30].
Statistical analysis
Virus neutralisation titres were analysed using linear mixed
models including time since vaccination and vaccine type (wt or
H2093C empty capsids) as factors and animal as a random effect.
Model selection proceeded by stepwise deletion of non-significant
(P.0.05) terms, starting from a model including time since
vaccination and vaccine and an interaction between them. The
total amount of virus produced following challenge was estimated
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for each animal by computing the area under the curve (AUC) for
copy number versus time using the trapezium rule. A Wilcoxon
rank-sum test was used to check for significant (P,0.05)
differences in AUCs, first between animals vaccinated with A22-
wt or A22-H2093C empty capsids and second between vaccinated
(with either capsid) and non-vaccinated animals.
Supporting Information
Text S1 Supporting Information. In Text S1, Figure S1
shows the configuration of the FMDV expression cassette cloned
into vaccinia virus transfer vector pBG200. Figure S2 shows the
extended structure of the VP3 GH-loop and its sequence
alignment to another A serotype strain. Figure S3 shows
disordered regions in the recombinant A22-H2093C capsid.
Table S1 provides X-ray data collection and refinement statistics.
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